IDH1 and central nervous system cancer: Isocitrate dehydrogenase 1 (IDH1) mutation is commonly shown in about 80% of low-grade gliomas, and patients with IDH1 mutation frequently have a favorable prognosis, thus IDH1 mutational status is a strong prognostic biomarker for gliomas [23].